Log in

NASDAQ:INVAInnoviva Stock Price, Forecast & News

-0.31 (-2.14 %)
(As of 05/26/2020 04:00 PM ET)
Today's Range
Now: $14.15
50-Day Range
MA: $13.43
52-Week Range
Now: $14.15
Volume659,393 shs
Average Volume805,806 shs
Market Capitalization$1.43 billion
P/E Ratio8.27
Dividend YieldN/A
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a long-acting beta2 agonist (LABA), vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate (FF); ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA and LABA. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Brisbane, California.
Read More
Innoviva logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.49 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:INVA
Previous SymbolNASDAQ:THRX



Sales & Book Value

Annual Sales$261.02 million
Cash Flow$1.70 per share
Book Value$3.38 per share


Net Income$157.29 million


Market Cap$1.43 billion
Next Earnings Date7/22/2020 (Estimated)

Receive INVA News and Ratings via Email

Sign-up to receive the latest news and ratings for INVA and its competitors with MarketBeat's FREE daily newsletter.

Innoviva (NASDAQ:INVA) Frequently Asked Questions

How has Innoviva's stock been impacted by COVID-19 (Coronavirus)?

Innoviva's stock was trading at $12.04 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, INVA stock has increased by 17.5% and is now trading at $14.15. View which stocks have been most impacted by Coronavirus.

When is Innoviva's next earnings date?

Innoviva is scheduled to release its next quarterly earnings announcement on Wednesday, July 22nd 2020. View our earnings forecast for Innoviva.

How were Innoviva's earnings last quarter?

Innoviva Inc (NASDAQ:INVA) issued its quarterly earnings results on Wednesday, April, 29th. The biotechnology company reported $0.59 EPS for the quarter, topping the Zacks' consensus estimate of $0.36 by $0.23. The biotechnology company had revenue of $78.68 million for the quarter. Innoviva had a net margin of 66.50% and a return on equity of 59.11%. View Innoviva's earnings history.

Has Innoviva been receiving favorable news coverage?

News stories about INVA stock have been trending negative on Wednesday, according to InfoTrie Sentiment. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Innoviva earned a coverage optimism score of -2.2 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news aboutInnoviva.

Who are some of Innoviva's key competitors?

What other stocks do shareholders of Innoviva own?

Who are Innoviva's key executives?

Innoviva's management team includes the following people:
  • Mr. Geoffrey Hulme, Interim Principal Exec. Officer (Age 52)
  • Ms. Marianne Zhen CPA, Chief Accounting Officer (Age 50)
  • Mr. Jeffrey A. Hagenah Ph.D., Chief Patent Counsel and VP
  • Dr. Kevin Kwok, Head of Talent Acquisition & Strategy

What is Innoviva's stock symbol?

Innoviva trades on the NASDAQ under the ticker symbol "INVA."

Who are Innoviva's major shareholders?

Innoviva's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (11.05%), State Street Corp (2.17%), First Eagle Investment Management LLC (1.73%), Invesco Ltd. (1.48%), Geode Capital Management LLC (0.99%) and Atom Investors LP (0.90%). Company insiders that own Innoviva stock include Geoffrey Hulme, George Bickerstaff, Innoviva, Inc, Marianne Zhen and Theodore J Jr Witek. View institutional ownership trends for Innoviva.

Which institutional investors are selling Innoviva stock?

INVA stock was sold by a variety of institutional investors in the last quarter, including Thrivent Financial for Lutherans, Invesco Ltd., BlackRock Inc., Chicago Equity Partners LLC, James Investment Research Inc., Wells Fargo & Company MN, Connor Clark & Lunn Investment Management Ltd., and Deutsche Bank AG. View insider buying and selling activity for Innoviva.

Which institutional investors are buying Innoviva stock?

INVA stock was acquired by a variety of institutional investors in the last quarter, including Matarin Capital Management LLC, SG Americas Securities LLC, Robeco Institutional Asset Management B.V., Acadian Asset Management LLC, Atom Investors LP, State Street Corp, Martingale Asset Management L P, and Eaton Vance Management. Company insiders that have bought Innoviva stock in the last two years include Geoffrey Hulme, George Bickerstaff, and Innoviva, Inc. View insider buying and selling activity for Innoviva.

How do I buy shares of Innoviva?

Shares of INVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Innoviva's stock price today?

One share of INVA stock can currently be purchased for approximately $14.15.

How big of a company is Innoviva?

Innoviva has a market capitalization of $1.43 billion and generates $261.02 million in revenue each year. The biotechnology company earns $157.29 million in net income (profit) each year or $1.43 on an earnings per share basis. Innoviva employs 6 workers across the globe.

What is Innoviva's official website?

The official website for Innoviva is www.inva.com.

How can I contact Innoviva?

Innoviva's mailing address is 1350 OLD BAYSHORE HIGHWAY SUITE 400, BURLINGAME CA, 94010. The biotechnology company can be reached via phone at 650-238-9600 or via email at [email protected]

This page was last updated on 5/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.